IntroductionChinese hamster ovary cells (CHO) are the expression system of choice in the bioproduction market for the manufacturing of bio‐therapeutic proteins. The first CHO cell lines were established by Puck in 1957, and since then many different lineages were established such as CHO‐S, CHO‐K1, CHOK1SV, DG44, and others. In general, CHO cells are robust, able to grow to high densities in suspension culture while maintaining high viability in large‐scale bioreactors, and can produce protein bio‐therapeutics in the 1–10 g/L range. Typically, stably transfected clones are generated to express bio‐pharmaceutically relevant proteins of interest. Once a cell line is developed, productivity and expression of a specific quality profile can be achieved through process optimization. The goal of such process development work is to maximize yield while maintaining critical quality attributes of the product. This is often achieved through optimization of culture medium, and production processes. Historically, mammalian cell culture medium and feed development has been based on iterative empirical approaches, which are both time consuming and costly. Although development efforts have improved by moving toward high‐throughput component screening in systems that are representative of large‐scale bioproduction processes, there continues to be a financial push to decrease time and effort associated with
Biotechnology Journal – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud